Korio, a Doylestown, a PA-based technology-first Randomization & Trial Supply Management (RTSM) company, raised $6.8M in funding.
The round was led by Excelerate Health Ventures, with participation from Boston Millennia Partners and other investors.
The company intends to use the funds to enhance its expansion, to bolster its team, and respond to increasing demand from life sciences and clinical research organizations.
Led by CEO Ryan Keane, Korio provides a clinical trial software platform that streamlines processes, and delivers predictable outcomes, all within shorter timeframes. By integrating the insights and expertise of the industry’s subject matter experts into its platform, Korio aims to challenge the status quo of complex, manual processes that have long plagued RTSM providers’ workflow and delivery models.
FinSMEs
10/10/2023